Search results for "Ventricular hypertrophy"

Identification of cardiac organ damage in arterial hypertension: insights by echocardiography for a comprehensive assessment

2020

: Arterial hypertension, a widespread disease, whose prevalence increases with age, represents a major risk factor for cardiovascular events, causing damage in several organs, including the heart. In this context, echocardiography has a clear and pivotal role, being able to assess cardiac morphology and detect haemodynamic changes induced by this disease. 2018 European Society of Cardiology/European Society of Hypertension guidelines on AH identified main echo parameters such as left ventricular mass, relative wall thickness and left atrial volume, for detecting cardiac organ damage. The present review highlights the advantage of additional echocardiographic parameters such as diastolic mea…

Metabolic syndrome in hypertensive patients: An unholy alliance

2014

For many years, it has been recognized that hypertension tends to cluster with various anthropometric and metabolic abnormalities including abdominal obesity, elevated triglycerides, reduced high-density lipoprotein cholesterol, glucose intolerance, insulin resistance and hyperuricemia. This constellation of various conditions has been transformed from a pathophysiological concept to a clinical entity, which has been defined metabolic syndrome (MetS). The consequences of the MetS have been difficult to assess without commonly accepted criteria to diagnose it. For this reason, on 2009 the International Diabetes Federation, the American Heart Association and other scientific organizations pro…

Should reduction of increased short‐term blood pressure variability be a target of antihypertensive therapy?

2021

Abstract It has long been known that blood pressure (BP) is characterized by marked short‐term fluctuations occurring within a 24‐h period and also by long‐term oscillations occurring over more prolonged periods of time. An increased short‐term blood pressure variability (BPV) appears to importantly contribute to target organ damage and to the enhanced cardiovascular risk of hypertensive patients, over and above the effect of an increase in mean BP levels. Reducing 24‐h mean BP is the main aim of antihypertensive therapy, but initial data are available that additional cardiovascular protection can be achieved by reducing BPV. However, to definitively prove the prognostic role of short‐term …

Influence of metabolic syndrome on hypertension-related target organ damage

2005

Relationship between left ventricular hypertrophy, diastolic function and extracardiac atherosclerosis in newly diagnosed hypertensives

2001

Different effects of losartan and delapril on plasma PAI-1 levels in patients with mild to moderate hypertension

2003

ACE probably influences the fibrinolytic system at acentral point by converting angiotensin I to angiotensin II,which increases PAI-1 activity. This effect appears to bemediated via the AT1-receptor in humans. The RAAS mayalso contribute to a reduction in t-PA production by degra-dation of bradykinin, since the latter increases the release ofprostacyclin, nitric oxide, and t-PA from endothelial cells.Accordingly, ACE inhibitors not only influence the fibrino-lytic system by a reduction of PAI-1 activity but also byincreasing t-PA activity [1–3]. However, few studies haveanalysed the effects of AT1-R antagonists on t-PA and PAI-1plasma levels and the in vivo effects of AT1-R antagonistson th…

Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury

2009

Mandarin translation of abstract Background and purpose:  The effects of a phosphodiesterase 4 (PDE4) inhibitor, roflumilast, on bleomycin-induced lung injury were explored in ‘preventive’ and ‘therapeutic’ protocols and compared with glucocorticoids. Experimental approach:  Roflumilast (1 and 5 mg·kg−1·d−1, p.o.) or dexamethasone (2.5 mg·kg−1·d−1, p.o.) was given to C57Bl/6J mice from day 1 to 14 (preventive) or day 7 to 21 (therapeutic) after intratracheal bleomycin (3.75 U·kg−1). In Wistar rats, roflumilast (1 mg·kg−1·d−1, p.o.) was compared with methylprednisolone (10 mg·kg−1·d−1, p.o.) from day 1 to 21 (preventive) or from day 10 to 21 (therapeutic), following intratracheal instillatio…

Markers of endothelial activation and left ventricular hypertrophy in essential hypertension

2003

Fetuin-A and left ventricular hypertrophy in essential hypertension.

2007

Korelācija starp ehokardiogrammu un EKG atradni slimniekiem ar kreisā kambara hipertorfiju

2018

KOPSAVILKUMS Pamatojums Kreisā kambara hipertrofijai tiek pievērsta uzmanība globālā līmenī. Kreisā kambara hipertrofijas esamība un tās pakāpes novērtēšana ir neatņemama sastāvdaļa ikdienā veiktiem mērījumiem kardioloģijā. Gan ehokardiogrāfija (EhoKG), gan elektrokardiogrāfija (EKG) ir labi zināmas metodes kreisā kamabara hipertrofijas un ar to saistītā riska novērtēšanai. Kreisā kambara hipertrofija tiek uzskatīta par neatkarīgu kardiovaskulārās mirstības un saslimstības riska faktoru. Mērķis Noteikt kreisā kambara hipertrofijas pazīmes, izmantojot elektrokardiogrāfijas un ehokardiogrāfijas metodes, un noskaidrot korelāciju starp kreisā kambara hipertrofijas pazīmēm EKG un EhoKG, kā arī n…